Hongjin Wang, Hengji Zhan, Bailin Pan, Leli Zeng, Zehua Chen, Sen Liu, Qiang Zhang, Xuwei Hong, Junlin Lu, Xinrou Lin, Xiao Zhao, Jiajian Lai, Kaiwen Jie, Ye Li, Jianmei Zhong, Shengmeng Peng, Siting Chen, Changhao Chen, Wenlong Zhong, Shaoxu Wu, Yihang Pan, Tianxin Lin, Xu Chen
Cancer Immunotherapy In article number 2501565, Xu Chen, Yihang Pan, Tianxin Lin, and co-workers have established a platform utilizing a CRISPR system-based bacterial outer membrane vesicle (OMV) for the efficient and cost-effective targeted delivery of plasmids. The intravesical administration of these engineered OMVs, which encoding CXCL-9 and IL-12, have been shown to effectively facilitating T-cell infiltration and activation. This process enhances the anti-tumor efficacy of OMV-mediated therapies and increases sensitivity to anti-PD-1/PD-L1 treatments. Consequently, this approach presents a novel strategy to address resistance to immunotherapy in the context of bladder cancer.